Do Weight-Loss Injections Cause Muscle Loss?

GLP-1 receptor agonists, such as semaglutide, and medications that act on both GIP and GLP-1 receptors, such as tirzepatide, have transformed the treatment of obesity. In addition to producing substantial weight loss, these medications can improve several metabolic outcomes.

However, as increasingly significant weight loss has become achievable with pharmacological treatment, an important question has emerged: How much of the weight lost is fat, and how much is lean or muscle mass?

The answer is more complex than simply looking at the number on the scale.

Weight Loss Does Not Mean Fat Loss Alone

During almost any substantial weight-loss intervention, the body does not lose adipose tissue exclusively. Some reduction in lean mass may also occur.

This phenomenon is not unique to GLP-1-based therapies. It can occur during calorie-restricted diets, after bariatric surgery, and with other interventions that produce significant weight loss.

One important distinction, however, is that lean mass is not synonymous with skeletal muscle mass.

Lean mass measurements include skeletal muscle but also body water, organs, connective tissue, glycogen, and other fat-free components. Therefore, a reduction in lean mass measured by methods such as DXA does not necessarily represent an equivalent loss of functional skeletal muscle. This distinction is essential when interpreting body-composition studies involving GLP-1 therapies.

What Do the Studies Show?

Clinical studies of semaglutide and tirzepatide confirm that some of the weight lost during treatment may come from lean mass. However, the magnitude varies considerably among studies.

In the STEP 1 DXA substudy with semaglutide 2.4 mg, substantial weight loss was accompanied by a reduction in lean mass. Nevertheless, lean mass as a proportion of total body weight increased, because fat mass decreased to an even greater extent.

In the SURMOUNT-1 DXA substudy with tirzepatide, approximately 25% of the weight reduction was attributed to lean mass, with the majority coming from fat mass.

Other studies have reported different proportions. These differences may be related to the specific medication, the magnitude and rate of weight loss, patient characteristics, diabetes status, methods used to assess body composition, physical activity, and nutritional interventions.

Therefore, the scientific evidence does not support the simplistic conclusion that “GLP-1 medications destroy muscle.”

A more accurate interpretation is that these therapies produce substantial fat loss and can also be accompanied by some loss of lean tissue. However, the extent to which this represents actual skeletal muscle loss—and, more importantly, whether it compromises strength and physical function—remains an area of active investigation.

Muscle Health Is About More Than Muscle Quantity

This is one of the most important aspects of the discussion.

When assessing muscle health, we should not consider muscle mass alone. Muscle quality, strength, and physical function are also clinically relevant.

In the SURPASS-3 MRI analysis, for example, tirzepatide was associated with a reduction in muscle volume proportional to the degree of weight loss, while fat-free muscle volume was maintained and muscle composition improved, including reduced fat infiltration.

Furthermore, available clinical trials have not consistently demonstrated clinically meaningful deterioration in physical function accompanying changes in lean mass.

This is why loss of lean mass, loss of skeletal muscle, and sarcopenia should not be considered interchangeable terms.

Who May Require Greater Attention?

Preserving muscle becomes particularly important in people who already have limited muscle reserves before starting treatment.

Older adults, people with frailty, sedentary individuals, and patients with pre-existing low muscle mass may be more vulnerable during rapid and substantial weight loss. Age, physical inactivity, and pre-existing sarcopenia are among the factors discussed in the literature as potential modifiers of lean tissue loss during GLP-1 treatment.

In these patients, monitoring body weight alone may not provide enough information.

How Can Muscle Be Preserved During Treatment?

The goal of modern obesity treatment should not simply be to achieve the greatest possible weight loss. We should also consider the quality of that weight loss.

The literature emphasizes strategies such as resistance exercise and adequate nutritional and protein intake to help preserve muscle during weight reduction. Resistance training, in particular, can optimize changes in body composition by helping preserve lean tissue while fat mass decreases.

For this reason, pharmacological treatment of obesity should ideally be incorporated into a broader strategy that includes individualized nutrition, physical activity, and clinical follow-up.

How Can Body Composition Be Monitored?

A scale tells us how much a person weighs, but it does not tell us what that weight is made of.

Depending on the clinical situation, body composition can be assessed using methods such as:

• Bioelectrical impedance analysis (BIA)

• Dual-energy X-ray absorptiometry (DXA)

• Muscle ultrasound

• Computed tomography (CT) or magnetic resonance imaging (MRI) in selected situations

In addition to muscle quantity, muscle strength and physical function may also be relevant, particularly in patients at increased risk of muscle loss.

This is important because clinical trials of GLP-1 therapies still have limitations regarding muscle assessment. Body composition is often measured only in subgroups of participants, while muscle strength, mobility, and physical function are not routinely evaluated.

Should We Be Afraid of GLP-1 Therapies Because of Muscle Loss?

No. The possibility of lean mass loss should not overshadow the substantial clinical benefits that appropriate weight reduction can provide for people living with obesity.

Instead, these findings reinforce the importance of treating obesity beyond the scale.

Rather than asking only:

“How many kilograms did the patient lose?” we should also ask:

“What did the patient lose, what was preserved, and what happened to muscle strength and physical function?”

The Take-Home Message

Successful obesity treatment is not simply about making the number on the scale smaller.

The goal should be to achieve a meaningful reduction in excess body fat while preserving skeletal muscle, strength, physical function, and metabolic health.

GLP-1-based therapies represent a major advance in obesity treatment. The next step is to make weight loss not only greater, but also healthier and better individualized.